Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer

Authors:

Abstract
No abstract available

This publication has 14 references indexed in Scilit: